Related Experiment Video
Updated: Jul 10, 2026
11:32
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options
Françoise Van Bambeke1, René R Reinert, Peter C Appelbaum
1Unité de Pharmacologie Cellulaire et Moléculaire, Université Catholique de Louvain, Brussels, Belgium. vanbambeke@facm.ucl.ac.be
Drugs
|November 7, 2007
Summary
Antibacterial resistance in Streptococcus pneumoniae is a growing global concern, impacting treatments. New drugs are in development, but their efficacy against resistant pneumococci requires further clinical validation.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Increasing global antibacterial resistance in Streptococcus pneumoniae affects beta-lactams and macrolides.
- Emergence of fluoroquinolone resistance and high prevalence of multi-drug resistant pneumococci (up to 40%) pose significant treatment challenges.
- Current treatment strategies for resistant pneumococcal infections are limited, with some agents facing toxicity or resistance selection concerns.
Purpose of the Study:
- To review the current landscape of antibacterial resistance in Streptococcus pneumoniae.
- To evaluate the efficacy and limitations of existing and emerging antibacterial agents against resistant pneumococci.
- To discuss the development pipeline for new drugs targeting multi-drug resistant strains.
Main Methods:
- Literature review of studies on Streptococcus pneumoniae resistance patterns.
- Analysis of current treatment guidelines and drug development trends.
- Evaluation of the spectrum of activity, resistance mechanisms, and safety profiles of various antibacterial classes.
Main Results:
- Beta-lactams remain a first-line option with optimized dosage, while macrolides require combination therapy.
- Ketolides and fluoroquinolones show potential for multi-drug resistant strains, but have associated toxicity and resistance concerns.
- Numerous novel agents targeting resistant strains are in development, many also aimed at MRSA, with clinical pneumococcal efficacy pending.
Conclusions:
- Optimized dosing of beta-lactams and combination macrolide therapy are current strategies for resistant pneumococcal infections.
- Emerging agents like ketolides and fluoroquinolones offer alternatives but require careful consideration of risks.
- Further clinical trials are essential to establish the efficacy of new drug candidates against multi-drug resistant Streptococcus pneumoniae.
Related Concept Videos
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:14Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
01:29Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...